Drug Design, Development and Therapy (Mar 2024)
Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice
Abstract
Ji-Eun Song,1 Hae-Jin Ko,2 A-Sol Kim1 1Department of Family Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea; 2Department of Family Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, KoreaCorrespondence: Hae-Jin Ko, Department of Family Medicine, School of Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu, 41944, Korea, Tel +82 53 200 6578, Fax +82 53 200 5480, Email [email protected]: Anti-obesity medications (AOMs), along with lifestyle interventions, are effective means of inducing and maintaining weight loss in patients with obesity. Although the efficacy of AOMs has been reported, there have been no direct comparisons of these drugs. Therefore, in the present study, we aimed to compare the efficacy of all the AOMs available in Korea in a real-world setting.Patients and Methods: The body weight and composition of 205 adults treated with phentermine, phentermine/topiramate, liraglutide, naltrexone/bupropion, lorcaserin, or orlistat for at least 6 months were analyzed at 2 month intervals. The prevalence of the achievement of a ≥ 5% weight loss and the changes in body composition were compared between participants using each AOM at each visit.Results: A total of 132 (64.4%) participants achieved ≥ 5% weight loss within 6 months (prevalence of ≥ 5% weight loss after 6 months: phentermine, 87.2%; phentermine/topiramate, 67.7%; liraglutide, 58.1%; naltrexone/bupropion, 35.3%; lorcaserin, 75%; orlistat, 50%). At each visit, after adjustment for age, sex, and baseline body weight, phentermine use was associated with a significantly higher prevalence of ≥ 5% weight loss than the use of the other AOMs, except for liraglutide. There were significant differences in the body weight, body mass index and body fat mass among the AOM groups by visit (P for interaction < 0.05), but not in their waist circumference, skeletal muscle mass, percentage body fat, or visceral fat area.Conclusion: All the AOMs were effective at inducing and maintaining weight loss, in the absence of significant changes in muscle mass, over a 6 month period, and the short-term use of phentermine and the long-term use of phentermine/topiramate or liraglutide would be practical choices for the treatment of obesity. However, further, large-scale studies are necessary to confirm these findings.Keywords: anti-obesity medication, body composition, weight loss, body weight maintenance, obesity
